Related Experiment Videos
Drug Trials Snapshots and Sexless Drug Labels
G Elliott Cook1, Erin E Wilhelm2
1Provider Resources, Inc, Erie, Pennsylvania.
JAMA Internal Medicine
|December 6, 2017
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Reasons for Premature Conclusion of Late Phase Clinical Trials: An Analysis of ClinicalTrials.gov Registered Phase III Trials.
Therapeutic innovation & regulatory science·2020
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
Journal of diabetes and its complications·2017
Data sharing for public health research: A qualitative study of industry and academia.
Communication & medicine·2015
Advancing a Vision for Regulatory Science Training.
Clinical and translational science·2015
Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial.
JAMA internal medicine·2026
Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome.
JAMA internal medicine·2026
Serologic Immunity to Hepatitis A and B in US Adults and High-Risk Populations.
JAMA internal medicine·2026
Management of Shoulder Pain in Primary Care: A Review.
JAMA internal medicine·2026
Medicare Advantage and Type 2 Diabetes Outcomes.
JAMA internal medicine·2026
Cendakimab for Eosinophilic Gastritis and Duodenitis in Japanese Adults and Adolescents: Results From a Phase 3 Randomized Controlled Trial.
The American journal of gastroenterology·2026
Buprenorphine Dispensed by Pharmacies and Administered in Emergency Departments in Urban and Rural Areas - United States, 2019-2025.
MMWR. Morbidity and mortality weekly report·2026
Rheumatoid Arthritis Guidelines Require Dietary Recommendations: An Overlooked Opportunity.
Clinical nutrition ESPEN·2026
Assessment of the impact of valproic acid co-administration on clozapine plasma concentrations in Tunisian patients.
Drug metabolism and personalized therapy·2026
Benefit-Risk of Voxelotor, Crizanlizumab, and L-Glutamine in Sickle Cell Disease: A Systematic Review.
The American journal of the medical sciences·2026